

## For Health Professionals Who Care for Cancer Patients

### Inside This Issue:

#### Provincial Systemic Therapy Program

**Revised Policy** Systemic Therapy Treatment Delivery Process

#### Medication Safety

Lidocaine Endotracheal Spray Limited to Single-Patient Use

#### Cancer Drug Manual®

**New** Enfortumab Vedotin, Isatuximab | **Revised** Aldesleukin, Bortezomib | IV Bag Size Selection Table | Editorial Board Changes

#### Revised Protocols, PPPOs & Patient Handouts

**BR** BRAJACTW, BRAJTTW, UBRAVKAD, BRAVTW, BRLACTWAC, BRLACTWACG, BRLATWAC | **GI** GIAAVCT, GIENACTRT, GIGAVCOX, GIGAVFFOX, GIGAVFFOXT | **GU** UGUAVIPNI, GUAVNIV, GUAVNIV4 | **HN** UHNAVNI, UHNAVNI4 | **LU** ULUAVNI, ULUAVNI4, ULUAVPMBF, ULUAVPMBF6, LUAVPPMBM, ULUAVPPMB, LULACATRT | **LY** LYEPOCHR, LYIVACR, LYNIV, LYNIV4, LYPALL | **MY** MYBORPRE | **SA** SAAVTW | **SM** USMAJNIV, USMAJNIV4, SMAVFIPI, USMAVIPNI, SMAVNIV, SMAVNIV4, SMAVPEM, SMAVPEM6

#### Resources and Contact Information

## Provincial Systemic Therapy Program

### Revised Policy: Systemic Therapy Treatment Delivery Process

The BC Cancer Provincial Systemic Therapy Program updated **Policy III-10: Systemic Therapy Treatment Delivery Process** effective 01 May 2021. All Systemic Therapy policies are available on the Shared Health Organizations Portal (SHOP) [BC Cancer page](#).

#### Why were changes made to Policy III-10?

Certain systemic therapy drugs require calculation of Body Surface Area (BSA). Currently, only the Mosteller formula is used to calculate BSA. Soon, some Clinical Trials protocols may require the use of the Dubois formula to calculate drug doses. Refer to individual protocols for specific calculation details.

#### What changes were made to Policy III-10?

Section	Change
<b>2.2 Prescription Requirements</b> <i>BSA Dosing</i>	<ul style="list-style-type: none"> <li>Added: "Exception: Clinical Trials protocols may require the use of the Dubois formula. Refer to protocol for specific calculation."</li> </ul>
<b>2.4 Pharmacy and Nursing Processes</b> <i>BSA Calculation</i>	<ul style="list-style-type: none"> <li>Added: "Exception: Clinical Trials protocols may require the use of the Dubois formula. Refer to protocol for specific calculation."</li> </ul>

## Medication Safety

### Lidocaine Endotracheal Spray Limited to Single-Patient Use

Lidocaine endotracheal spray (LIDODAN Endotracheal) is a topical anesthetic used within several departments at BC Cancer. LIDODAN Endotracheal is supplied as a canister containing 250 metered doses and a detachable nozzle. Until now, a single canister has been used for multiple patients by attaching a new single-use nozzle for each patient. Effective 19 July 2021, lidocaine endotracheal spray canisters are to be single-patient use at BC Cancer.

The 2018 Medication Administration Accreditation standards state that when a multi-dose injectable medication vial is used for multiple patients, that the vial should not be kept in the patient care area in order to reduce the risk of cross-contamination and spread of infection amongst patients. In contrast to multi-dose vials, lidocaine endotracheal spray canisters must be used in close proximity to patients due to drug delivery via the attached nozzle. Therefore, to comply with Accreditation Canada standards and best practices to reduce the risk of cross-contamination and spread of infection among patients, it is necessary to limit lidocaine endotracheal spray canisters to single-patient use.

*On behalf of Professional Practice Nursing, Provincial Pharmacy and Infection Control*

## Cancer Drug Manual<sup>©</sup>

All BC Cancer Drug Manual<sup>©</sup> documents can be accessed from the [Cancer Drug Manual<sup>©</sup>](#) home page on the BC Cancer website.

### New Documents

Note that the following drugs are not BC Cancer Benefit Drugs and require application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monographs and Patient Handout are made available for reference only.

The **Enfortumab Vedotin Interim Monograph** has been developed. Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, an adhesion protein located on the surface of cells. The ADC is comprised of a monoclonal antibody component (AGS-22C3) conjugated to a small molecule microtubule-disrupting agent (monomethyl auristatin E). Enfortumab vedotin is used in the treatment of urothelial carcinoma. Usual dosing is 1.25 mg/kg IV given on days 1, 8 and 15 of a 28-day cycle.

Highlights from this document include:

- extravasation may cause skin and soft tissue reactions such as erythema, swelling, pain, secondary cellulitis, bullae, and exfoliation; onset may be delayed (e.g., 24 hours) and symptoms may worsen before resolving over 1-4 weeks
- hyperglycemia and diabetic ketoacidosis have been reported in patients with and without pre-existing diabetes mellitus
- ocular disorders are frequent; consider artificial tears as prophylaxis for dry eyes
- peripheral neuropathy is common and predominantly sensory; it occurs in patients with and without pre-existing neuropathy

Enfortumab vedotin has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Cancer Hazardous Drug List**.

The **Isatuximab Interim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Jesse Shustik (medical oncologist) and Louisa Pang (clinical pharmacist) of the BC Cancer Lymphoma and Myeloma Tumour Group. Isatuximab is an IgG1-derived monoclonal antibody that targets CD38, a transmembrane glycoprotein expressed in hematological malignancies. Isatuximab is used in combination with pomalidomide and dexamethasone in the treatment of multiple myeloma. Isatuximab is administered in 4-week cycles; usual dosing is 10 mg/kg IV weekly in the first cycle, followed by 10 mg/kg on days 1 and 15 for all subsequent cycles.

Highlights from these documents include:

- infusion-related reactions are common and usually start with the first infusion; pre-medications are required
- hematologic toxicities are frequently reported
- serious and potentially fatal neutropenic infections have occurred
- rare, but serious side effects include cytokine release syndrome, arrhythmia/atrial fibrillation and secondary primary malignancies

**Isatuximab** has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Cancer Hazardous Drug List**.

### Revised Documents

Highlights of key changes are listed below:

#### **Aldesleukin Monograph and Chemotherapy Preparation and Stability Chart**

*Uses:* updated Health Canada approved indications

*Cautions:* added CNS metastases and bacterial infections

*Pregnancy:* added evidence from animal studies

*Side Effects:* added new paragraph for intralesional administration

*Supply and Storage:* updated manufacturer (now SteriMax)

*Solution Preparation and Compatibility (Additional Information):* updated compatibility information

*Parenteral Administration table:* added in-line filter information; added intralesional route

*Dosing:* added dosing for intralesional use; updated references for children's dosing (expert review provided by Dr. Jennifer Kendrick, Children's & Women's Health Centre of British Columbia)

**Chemotherapy Preparation and Stability Chart:** added preparation instructions for intralesional use

#### **Bortezomib Monograph and Chemotherapy Preparation and Stability Chart**

*Supply and Storage:* added Juno brand; updated contract brands

**Chemotherapy Preparation and Stability Chart:** added Juno brand

### IV Bag Size Selection Table

IV bag sizes suggested for drugs with concentration-dependent stability or with large drug volumes have been extracted from the BC Cancer Chemotherapy Preparation and Stability Chart and tabulated in a document called the **BC Cancer IV Bag Size Selection Table**. The IV Bag Size Selection Table can be accessed from the [Cancer Drug Manual<sup>©</sup>](#) home page on the BC Cancer website.

## CDM Editorial Board Changes

The Cancer Drug Manual<sup>®</sup> Editorial Review Board would like to bid farewell to **Dr. Deepa Wadhwa** (medical oncologist, BC Cancer – Kelowna) as she steps down from the board pending her move to Ontario. Thank you, Deepa, for your many contributions to the Cancer Drug Manual<sup>®</sup> and best wishes in your future endeavours.

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>BR   Breast</b>				
<b>BRAJACTW</b>	Neoadjuvant or Adjuvant Therapy for Early Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>BRAJTTW</b>	Adjuvant Therapy for Breast Cancer using Weekly Paclitaxel and Trastuzumab	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>UBRAVKAD</b>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)	<i>Tests revised</i>	----	----
<b>BRAVTV</b>	Palliative Therapy for Metastatic Breast Cancer using Weekly Paclitaxel (3 Weeks out of 4 Weeks Schedule)	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>BRLACTWAC</b>	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>BRLACTWACG</b>	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>BRLATWAC</b>	Neoadjuvant Therapy for Locally Advanced Breast Cancer using Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>GI   Gastrointestinal</b>				
<b>GIAAVCT</b>	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using Carboplatin and Weekly Paclitaxel	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>GIENACTRT</b>	Neoadjuvant Treatment of Esophageal and Gastroesophageal Carcinomas using Carboplatin, Paclitaxel and Radiation Therapy	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>GIGAVCOX</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Capecitabine and Oxaliplatin	<i>Treatment duration updated</i>	----	----

**REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)**

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GIGAVFFOX</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil and Leucovorin	<i>Treatment duration updated</i>	----	----
<b>GIGAVFFOXT</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<i>Treatment duration updated</i>	----	----
<b>GU   Genitourinary</b>				
<b>UGUAVIPNI</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Ipilimumab and Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
<b>GUAVNIV</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
<b>GUAVNIV4</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
<b>HN   Head and Neck</b>				
<b>UHNAVIV</b>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
<b>UHNAVIV4</b>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
<b>LU   Lung</b>				
<b>ULUAVNIV</b>	Treatment of Advanced Non-Small Cell Lung Cancer using Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
<b>ULUAVNIV4</b>	Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
<b>ULUAVPMBF</b>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer using Pembrolizumab	<i>Eligibility clarified</i>	----	----
<b>ULUAVPMBF6</b>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	<i>Eligibility clarified</i>	----	----
<b>LUAVPPMBM</b>	Maintenance Therapy of Advanced Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed and Pembrolizumab	<i>Eligibility clarified</i>	----	----
<b>ULUAVPPMB</b>	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab	<i>Eligibility clarified</i>	----	----

**REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)**

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LULACATRT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Carboplatin and Paclitaxel with Radiation Therapy	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>LY   Lymphoma</b>				
LYEPOCHR	Treatment of Lymphoma with Dose-Adjusted Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone and Rituximab with Intrathecal Methotrexate	<i>Tests revised</i>	<i>Tests revised</i> <b>Inpatient PPPO</b>	----
LYIVACR	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab	<i>Tests updated</i>	<i>Tests updated</i>	----
LYNIV	Treatment of Relapsed or Refractory Hodgkin Lymphoma using Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
LYNIV4	Treatment of Relapsed or Refractory Hodgkin Lymphoma using 4-Weekly Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
LYPALL	Lymphoma Palliative Chemotherapy	<i>Treatment options clarified</i>	----	----
<b>MY   Myeloma</b>				
MYBORPRE	Treatment of Multiple Myeloma using Bortezomib, Dexamethasone with or without Cyclophosphamide as Induction Pre-Stem Cell Transplant	<i>Eligibility revised; dexamethasone dosing clarified</i>	----	----
<b>SA   Sarcoma</b>				
SAAVTW	Metastatic or Unresectable Angiosarcoma using Weekly Paclitaxel (3 Weeks out of 4 Weeks Schedule)	<i>Paclitaxel bag size clarified</i>	<i>Paclitaxel bag size clarified</i>	----
<b>SM   Skin and Melanoma</b>				
USMAJNIV	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
USMAJNIV4	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using 4-Weekly Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
SMAVFIPI	First-Line Treatment of Unresectable or Metastatic Melanoma using Ipilimumab	<i>Eligibility and Exclusions revised</i>	----	----
USMAVIPNI	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab and Nivolumab	<i>Nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i> <b>Maintenance PPPO</b>	----
SMAVNIV	Treatment of Unresectable or Metastatic Melanoma using Nivolumab	<i>Eligibility and Exclusions revised; nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----

**REVISED Protocols, PPPOs and Patient Handouts** (*revisions in respective columns*)

<b>Protocol Code</b>	<b>Protocol Title</b>	<b>Protocol</b>	<b>PPPO</b>	<b>Handout</b>
<b>SMAVNIV4</b>	Treatment of Unresectable or Metastatic Melanoma using 4-Weekly Nivolumab	<i>Eligibility and Exclusions revised; nivolumab bag size clarified</i>	<i>Nivolumab bag size clarified</i>	----
<b>SMAVPEM</b>	Treatment of Unresectable or Metastatic Melanoma using Pembrolizumab	<i>Eligibility and Exclusions revised</i>	----	----
<b>SMAVPEM6</b>	Treatment of Unresectable or Metastatic Melanoma using 6-Weekly Pembrolizumab	<i>Eligibility and Exclusions revised</i>	----	----

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
Nurse Educators	604-877-6000 x 672638	<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Manufacturer Patient Assistance Programs: <a href="http://www.bccancer.bc.ca/mpap">http://www.bccancer.bc.ca/mpap</a>		
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCCancerPPNAdmin@ehcnet.phsa.ca">BCCancerPPNAdmin@ehcnet.phsa.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)  
 Fatima Ladha, BScPharm, PharmD (Assistant Editor)  
 Mario de Lemos, PharmD, MSc(Oncol)

Jeevan Dosanjh, RN, BScN  
 Alina Gerrie, MD, MPH, FRCPC  
 Alison Pow, BScPharm